Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIVC for Olaparib Tablets in Solid Tumors
NCT03553108Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib in solid tumor (4 arms), sponsored by AstraZeneca. Primary endpoints: Percentage of Maximum Plasma Concentration and Percentage of Area Under the Curve. Started May 2018; status: completed.
02
Drugs
olaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03553108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553108.